Good morning, everyone, and welcome to another working week. This is not just any ordinary week for us, however, since it marks the 10th anniversary that we have been working on Pharmalot. This calls for a few celebratory cups of stimulation and, of course, we invite you to join us. We also wish to thank you for the long-standing support you have shown over the years. Meanwhile, as always, we invite you to join us and peruse the usual lineup of tidbits. Hope you have a smashing day and do keep in touch.
Representative Tom Price last year purchased shares in Zimmer Biomet days before introducing a bill that would have directly benefited the company, raising new ethics concerns for President-elect Donald Trump’s pick to lead the Department of Health and Human Services, CNN reports. The Trump transition team alleged this was “junk reporting” and that Price stock trades were orchestrated by a broker-directed account.
Biogen agreed to pay $1.25 billion in cash to license all of Forward Pharma’s intellectual property, MarketWatch notes. The companies have been in a patent dispute over rival multiple sclerosis drugs, and a decision is expected by the middle of this year. Biogen says this would “clarify and strengthen our intellectual property for Tecfidera,” a multiple sclerosis drug that is its biggest seller, but it doesn’t resolve ongoing patent disputes in the US or Europe.
About the Author Reprints
